Pfizer Inc. and Merck KGAAreported a Phase III failure for their PD-L1 inhibitor Bavencio (avelumab) in second-line non-small cell lung cancer on Feb. 15, which at least one analyst sees as portending a poor outcome for an ongoing Phase III study in the first-line setting for this tumor type.
Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer
The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.
